Raymond James Financial
ARQT icon

Raymond James Financial’s Arcutis Biotherapeutics ARQT Stock Holding History

Raymond James Financial’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.53M Buy
149,867
+4,918
+3% +$126K ﹤0.01% 2886
2025
Q4 		$4.21M Buy
144,949
+84,875
+141% +$2.17M ﹤0.01% 2658
2025
Q3 		$1.13M Buy
60,074
+6,451
+12% +$102K ﹤0.01% 3600
2025
Q2 		$752K Sell
53,623
-4,423
-8% -$62K ﹤0.01% 3754
2025
Q1 		$908K Buy
+58,046
New +$818K ﹤0.01% 3567

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return